193 related articles for article (PubMed ID: 32319481)
1. Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.
Ahir M; Upadhyay P; Ghosh A; Sarker S; Bhattacharya S; Gupta P; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2020 May; 8(10):2939-2954. PubMed ID: 32319481
[TBL] [Abstract][Full Text] [Related]
2. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells.
Kapadia CH; Ioele SA; Day ES
J Biomed Mater Res A; 2020 Mar; 108(3):601-613. PubMed ID: 31742868
[TBL] [Abstract][Full Text] [Related]
3. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
Devulapally R; Sekar NM; Sekar TV; Foygel K; Massoud TF; Willmann JK; Paulmurugan R
ACS Nano; 2015 Mar; 9(3):2290-302. PubMed ID: 25652012
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
7. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
10. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
11. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
12. Polymer-Initiating Caveolae-Mediated Endocytosis and GSH-Responsive MiR-34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy.
Han TY; Huan ML; Cai Z; He W; Zhou SY; Zhang BL
Adv Healthc Mater; 2023 Dec; 12(32):e2302094. PubMed ID: 37827986
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells.
Al-Othman N; Hammad H; Ahram M
Gene; 2018 Oct; 675():128-135. PubMed ID: 29964098
[TBL] [Abstract][Full Text] [Related]
14. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.
Li Y; Duo Y; Bi J; Zeng X; Mei L; Bao S; He L; Shan A; Zhang Y; Yu X
Int J Nanomedicine; 2018; 13():1241-1256. PubMed ID: 29535520
[TBL] [Abstract][Full Text] [Related]
16. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
[No Abstract] [Full Text] [Related]
17. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
18. IMP3 promotes TNBC stem cell property through miRNA-34a regulation.
Huang QD; Zheng SR; Cai YJ; Chen DL; Shen YY; Lin CQ; Hu XQ; Wang XH; Shi H; Guo GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2688-2696. PubMed ID: 29771420
[TBL] [Abstract][Full Text] [Related]
19. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.
Wang Y; Xie Y; Kilchrist KV; Li J; Duvall CL; Oupický D
ACS Appl Mater Interfaces; 2020 Jan; 12(4):4308-4322. PubMed ID: 31939276
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
